POLYNEURON
Basel
About POLYNEURON
Polyneuron is a developer of novel therapeutics intended to facilitate the treatment of antibody-mediated autoimmune diseases. The company's biodegradable glycopolymers-based therapeutics selectively eliminate the pathological autoantibodies, while leaving the rest of the immune system intact, enabling medical practitioners to treat patients with immune disorders in a safe and effective manner.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: Less than $1M
- Total funding: $45.0M
- Funding stage: Early Stage Venture
- Last round: Series A (Sep 2020)
- Website: polyneuron.com
- Phone: +41788371011
Industries & Categories
Biotechnology, Communities, Medical, Medical Device
Social Profiles
Canonical: https://fsome.com/organization/polyneuron-62015 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.